← Back to Search

Anticholinergic

Scopolamine for Memory Loss

Q: Does the eligibility for this trial extend to individuals beyond 35 years of age?

This trial seeks patients aged between 18 to 55 years old. Seperately, there are 149 clinical trials available for minors and 737 studies that cater to people over 65.

Q: How many subjects are enrolled in this exploration?

Affirmative. Clinicaltrials.gov's records demonstrate that this medical trial, which was first posted on August 1st 2019, is currently seeking participants. 60 people must be recruited from a single centre to complete the study.

Q: Is this research project currently recruiting participants?

According to the information provided on clinicaltrials.gov, this investigation is actively seeking applicants – it was first published on August 1st 2019 and has been recently modified as of October 20th 2022.

Q: What qualifications must a participant possess to be eligible for this medical experiment?

This clinical trial is recruiting 60 individuals between ages 18 and 55 who are currently exhibiting symptomology associated with aura. In order to be eligible, volunteers must meet the following prerequisites: age range of 18-55 years old; <a href="https://www.withpower.com/clinical-trials/all">all</a> races/ethnicities and genders accepted; able to read, understand, and provide signed informed consent prior to screening; healthy aside from a history of <a href="https://www.withpower.com/clinical-trials/epilepsy">epilepsy</a> as determined by medical records, physical examination (PE), laboratory evaluations, electrocardiogram (ECG); body mass index within the parameters of 18-35 kg / m2.

Phase < 1

Recruiting

Led By Bradley C Lega, MD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 - 55 years, all races/ethnicities, and both genders are eligible.

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, at day 2 post-intervention (approx. within 1-3 hrs)

Awards & highlights

Study Summary

This trial will investigate how an anticholinergic drug affects areas of the brain involved in memory and brain activity. Participants will receive the drug or a placebo to compare brain activity changes.

Who is the study for?

This trial is for adults aged 18-55 with epilepsy, in good health otherwise, and scheduled for intracranial surgery. They must have a BMI of 18-35 kg/m2 and be able to consent. Excluded are those with significant health issues like heart problems, liver failure, certain neurological conditions, glaucoma, gastrointestinal blockages or pregnant women.Check my eligibility

What is being tested?

The study tests how scopolamine affects memory-related brain activity in epileptic patients during surgery. Participants receive either the drug or a placebo on different days while completing memory tasks. Brain activity is recorded to see if scopolamine influences memory encoding or retrieval.See study design

What are the potential side effects?

Scopolamine can cause dry mouth, blurred vision, dizziness, confusion and difficulty urinating. It may also worsen conditions like BPH (enlarged prostate), narrow-angle glaucoma or myasthenia gravis.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 55 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, at day 2 post-intervention (approx. within 1-3 hrs)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, at day 2 post-intervention (approx. within 1-3 hrs)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, at day 2 post-intervention (approx. within 1-3 hrs) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)

Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Scopolamine (5ug/kg)Experimental Treatment1 Intervention

Subjects will receive a dose of scopolamine (5ug/kg) on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session. If the patient completed the sham session already, this session will take place the day following the initial session, or at least four half-lives after the first session.

Group II: PlaceboPlacebo Group1 Intervention

Subjects will receive saline (5ug/kg) via IV on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session. If the patient completed the scopolamine session already, this session will take place the day following the initial session, or at least four half-lives after the first session.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,053,739 Total Patients Enrolled

National Institute of Neurological Disorders and Stroke (NINDS)NIH

1,340 Previous Clinical Trials

649,304 Total Patients Enrolled

Bradley C Lega, MDPrincipal InvestigatorUniversity of Texas Southwestern Medical Center

Media Library

Scopolamine (Anticholinergic) Clinical Trial Eligibility Overview. Trial Name: NCT05594017 — Phase < 1

Memory Loss Research Study Groups: Scopolamine (5ug/kg), Placebo

Memory Loss Clinical Trial 2023: Scopolamine Highlights & Side Effects. Trial Name: NCT05594017 — Phase < 1

Scopolamine (Anticholinergic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05594017 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the eligibility for this trial extend to individuals beyond 35 years of age?

"This trial seeks patients aged between 18 to 55 years old. Seperately, there are 149 clinical trials available for minors and 737 studies that cater to people over 65."

Answered by AI

How many subjects are enrolled in this exploration?

"Affirmative. Clinicaltrials.gov's records demonstrate that this medical trial, which was first posted on August 1st 2019, is currently seeking participants. 60 people must be recruited from a single centre to complete the study."

Answered by AI

Is this research project currently recruiting participants?

"According to the information provided on clinicaltrials.gov, this investigation is actively seeking applicants – it was first published on August 1st 2019 and has been recently modified as of October 20th 2022."

Answered by AI

What qualifications must a participant possess to be eligible for this medical experiment?

"This clinical trial is recruiting 60 individuals between ages 18 and 55 who are currently exhibiting symptomology associated with aura. In order to be eligible, volunteers must meet the following prerequisites: age range of 18-55 years old; all races/ethnicities and genders accepted; able to read, understand, and provide signed informed consent prior to screening; healthy aside from a history of epilepsy as determined by medical records, physical examination (PE), laboratory evaluations, electrocardiogram (ECG); body mass index within the parameters of 18-35 kg / m2."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pharmacological Modulation of Brain Oscillations in Memory Processing

Bradley Lega 2019. "Pharmacological Modulation of Brain Oscillations in Memory Processing". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05594017.

All > Epilepsy